NEUROPACE, INC. Research and Development Expense
NEUROPACE, INC. (NPCE) reported Research and Development Expense of $6.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- NEUROPACE, INC. research and development expense for the quarter ending 2026-06-30 was $6.90M, a 0.77% increase year-over-year.
- NEUROPACE, INC. research and development expense for the quarter ending 2026-03-31 was $7.19M, a 3.37% decline year-over-year.
- NEUROPACE, INC. research and development expense for the quarter ending 2025-12-31 was $7.03M, a 16.15% increase year-over-year.
- NEUROPACE, INC. research and development expense for the quarter ending 2025-09-30 was $6.58M, a 14.29% increase year-over-year.
- NEUROPACE, INC. research and development expense for fiscal 2025 was $27.89M, a 17.90% increase from fiscal 2024.
- NEUROPACE, INC. research and development expense for fiscal 2024 was $23.65M, a 13.84% increase from fiscal 2023.
- NEUROPACE, INC. research and development expense for fiscal 2023 was $20.78M, a 5.32% decline from fiscal 2022.
- NEUROPACE, INC. research and development expense for fiscal 2022 was $21.95M, a 20.51% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.90M 10-Q · filed 2026-08-11 | $14.09M 10-Q · filed 2026-08-11 | $21.11M derived: sum of 3 quarters · filed 2026-08-11 | $27.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.19M 10-Q · filed 2026-05-12 | $14.22M derived: sum of 2 quarters · filed 2026-05-12 | $20.79M derived: sum of 3 quarters · filed 2026-05-12 | $27.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $7.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $13.60M derived: sum of 2 quarters · filed 2026-03-03 | $20.45M derived: sum of 3 quarters · filed 2026-08-11 | $27.89M 10-K · filed 2026-03-03 |
| 2025-09-30 | $6.58M 10-Q · filed 2025-11-04 | $13.42M derived: sum of 2 quarters · filed 2026-08-11 | $20.86M 10-Q · filed 2025-11-04 | $26.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.84M 10-Q · filed 2026-08-11 | $14.29M 10-Q · filed 2026-08-11 | $20.34M derived: sum of 3 quarters · filed 2026-08-11 | $26.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.44M 10-Q · filed 2026-05-12 | $13.49M derived: sum of 2 quarters · filed 2026-05-12 | $19.24M derived: sum of 3 quarters · filed 2026-05-12 | $25.31M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $11.80M derived: sum of 2 quarters · filed 2026-03-03 | $17.87M derived: sum of 3 quarters · filed 2026-03-03 | $23.65M 10-K · filed 2026-03-03 |
| 2024-09-30 | $5.75M 10-Q · filed 2025-11-04 | $11.82M derived: sum of 2 quarters · filed 2025-11-04 | $17.60M 10-Q · filed 2025-11-04 | $22.98M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $6.07M 10-Q · filed 2025-08-12 | $11.85M 10-Q · filed 2025-08-12 | $17.23M derived: sum of 3 quarters · filed 2025-08-12 | $22.02M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $5.78M 10-Q · filed 2025-05-13 | $11.16M derived: sum of 2 quarters · filed 2025-05-13 | $15.96M derived: sum of 3 quarters · filed 2025-05-13 | $21.30M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $10.17M derived: sum of 2 quarters · filed 2025-03-04 | $15.52M derived: sum of 3 quarters · filed 2025-03-04 | $20.78M 10-K · filed 2025-03-04 |
| 2023-09-30 | $4.79M 10-Q · filed 2024-11-12 | $10.14M derived: sum of 2 quarters · filed 2024-11-12 | $15.40M 10-Q · filed 2024-11-12 | $20.49M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $5.34M 10-Q · filed 2024-08-13 | $10.61M 10-Q · filed 2024-08-13 | $15.70M derived: sum of 3 quarters · filed 2024-08-13 | $21.31M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $5.26M 10-Q · filed 2024-05-08 | $10.35M derived: sum of 2 quarters · filed 2024-05-08 | $15.96M derived: sum of 3 quarters · filed 2024-05-08 | $21.63M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $10.70M derived: sum of 2 quarters · filed 2024-03-05 | $16.37M derived: sum of 3 quarters · filed 2024-03-05 | $21.95M 10-K · filed 2024-03-05 |
| 2022-09-30 | $5.61M 10-Q · filed 2023-11-06 | $11.28M derived: sum of 2 quarters · filed 2023-11-06 | $16.86M 10-Q · filed 2023-11-06 | $22.20M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $5.67M 10-Q · filed 2023-08-08 | $11.25M 10-Q · filed 2023-08-08 | $16.59M derived: sum of 3 quarters · filed 2023-08-08 | $20.92M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $5.58M 10-Q · filed 2023-05-04 | $10.92M derived: sum of 2 quarters · filed 2023-05-04 | $15.25M derived: sum of 3 quarters · filed 2023-05-04 | $19.69M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $9.67M derived: sum of 2 quarters · filed 2023-03-02 | $14.11M derived: sum of 3 quarters · filed 2023-03-02 | $18.21M 10-K · filed 2023-03-02 |
| 2021-09-30 | $4.33M 10-Q · filed 2022-11-08 | $8.77M derived: sum of 2 quarters · filed 2022-11-08 | $12.87M 10-Q · filed 2022-11-08 | $16.79M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $4.44M 10-Q · filed 2022-08-11 | $8.54M 10-Q · filed 2022-08-11 | $12.46M derived: sum of 3 quarters · filed 2022-08-11 | $16.15M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.10M 10-Q · filed 2022-05-12 | $8.02M derived: sum of 2 quarters · filed 2022-05-12 | $11.71M derived: sum of 3 quarters · filed 2022-05-12 | $14.96M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $7.61M derived: sum of 2 quarters · filed 2022-03-10 | $10.86M derived: sum of 3 quarters · filed 2022-03-10 | $15.70M 10-K · filed 2022-03-10 |
| 2020-09-30 | $3.69M 10-Q · filed 2021-11-10 | $6.94M derived: sum of 2 quarters · filed 2021-11-10 | $11.78M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.25M 10-Q · filed 2021-08-12 | $8.09M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $4.83M 10-Q · filed 2021-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |